DGAP-News: Formycon AG / Key word(s): Financing/Study 
Formycon receives approval for early action for COVID-19 drug FYB207 as part of a grant from the Bavarian Ministry of 
Economic Affairs, Regional Development and Energy (StMWi) 
2021-04-27 / 07:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Press Release // April 27, 2021 
Formycon receives approval for early action for COVID-19 drug FYB207 as part of a grant from the Bavarian Ministry of 
Economic Affairs, Regional Development and Energy (StMWi) 
- Consideration of FYB207 in the funding call "BayTherapie2020" 
- Funded project includes development activities of FYB207 through to completion of Phase IIa clinical trials 
- Requested funding amount of approximately Euro 11 million 
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced the approval of early action for its COVID-19 
drug (FYB207) by the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi). The requested 
grant is expected to support the further development of FYB207 until the completion of clinical phase IIa and has an 
anticipated volume of approximately Euro 11 million. The total amount of funding will be determined upon receipt of the 
formal notice of approval. 
The early start of the project enables Formycon to implement the preclinical development activities as planned and to 
manufacture the test product under GMP conditions before the final approval is granted. FYB207 is expected to move into 
Phase I/IIa clinical testing in the fourth quarter of 2021. 
As part of the Bavarian therapy strategy to combat the COVID-19 pandemic, the Free State of Bavaria has created the 
conditions for funding development and innovation projects aimed at opening up new therapy options for treating the 
infectious disease induced by the SARS-CoV-2 coronavirus with the funding call "BayTherapie 2020" and the provision of 
a total of up to Euro 50 million. 
SARS-CoV-2 and other coronaviruses use the protein ACE2 on the surface of human cells as a portal of entry for 
respiratory infections. Formycon has therefore fused the human ACE2 protein to the constant part of human 
immunoglobulin G4 (IgG4) using computational structural design and created FYB207, a highly effective SARS-CoV-2 
blocker that completely prevents cell infection in vitro. 
Compared to vaccines and therapeutic antibodies, the ACE2-IgG4-Fc fusion protein is maximally protected against viral 
escape by mutation. The risk of infection amplification by vaccines and IgG1 antibodies described for coronaviruses is 
minimized by using the IgG4 portion in the fusion. FYB207 also has inherent enzymatic activity that may provide 
patients with additional lung and cardiovascular protection. In addition, FYB207 can potentially be used for all 
coronaviruses that use ACE2 as a port of entry. 
Recently, Formycon AG, together with its academic partners Prof. Ulrike Protzer, Chair of Virology, and Prof. Johannes 
Buchner, Chair of Biotechnology at the Technical University of Munich, published new results on the in vitro 
neutralization of SARS-CoV-2 variants by Formycon's COVID-19 drug FYB207. These showed that FYB207 had an even stronger 
effect against the B.1.1.7 mutant of the virus, which is considered particularly infectious, than against earlier 
variants. 
"We are pleased that the Bavarian State Ministry of Economic Affairs, Regional Development and Energy has granted an 
early start to our funding application. Our project prevailed in a highly competitive process and, in addition to the 
associated scientific and technological recognition of our development approach by renowned reviewers, the support of 
public funding is a key component of project financing. We want FYB207 to be an important treatment option for COVID-19 
patients that saves lives. At the same time, we also want to contribute to the prevention of outbreaks of new 
coronaviruses in the future," comments Formycon CFO Dr. Nicolas Combé. 
About Formycon: 
Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The 
company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value 
chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing 
approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible 
with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its 
extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a 
COVID-19 fusion protein. 
Contact: 
Sabrina Müller 
Senior Manager Corporate Communications and Investor Relations 
Formycon AG 
Fraunhoferstr. 15 
82152 Martinsried/Planegg/Germany 
Phone: +49 (0) 89 - 86 46 67 149 
Fax + 49 (0) 89 - 86 46 67 110 
Sabrina.Mueller@formycon.com // www.formycon.com 
Disclaimer: 
This press release may contain forward-looking statements and information which are based on our current expectations 
and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material 
differences between the actual future results, financial situation, performance of the company, development of the 
products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the 
research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other 
governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent 
litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does 
not provide any representation, warranties or any other guarantees that the products will receive the necessary 
regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no 
obligation to update these forward-looking statements or to correct them in case of developments which differ from 
those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or 
subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public 
offering intended. This document and the information contained therein may not be distributed in or into the United 
States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would 
be prohibited. This document does not constitute an offer for the sale of securities in the United States. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-04-27 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Formycon AG 
              Fraunhoferstraße 15 
              82152 Planegg-Martinsried 
              Germany 
Phone:        089 864667 100 
Fax:          089 864667 110 
Internet:     www.formycon.com 
ISIN:         DE000A1EWVY8 
WKN:          A1EWVY 
Indices:      Scale 30 
Listed:       Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, 
              Tradegate Exchange 
EQS News ID:  1188288 
 
End of News   DGAP News Service 
=------------

1188288 2021-04-27


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1188288&application_name=news

(END) Dow Jones Newswires

April 27, 2021 01:01 ET (05:01 GMT)